All cancer types
Results
Phase 1
This trial looked at a treatment called OXi4503 for people with an advanced solid tumour (not lymphoma or leukaemia). This trial was supported by Cancer Research UK.
Cancers need a blood supply to grow and spread. OXi4503 is a type of biological therapy called a vascular disrupting agent. This means it can reduce or shut down the blood supply to cancer cells. When this happens, the cancer cells cannot get the oxygen and nutrients they need to survive and grow, and so they die.
Recruitment start: 12 May 2005
Recruitment end: 28 January 2010
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Gordon Rustin
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
OXiGENE
This is Cancer Research UK trial number CRUKD/05/035.
Last reviewed: 02 Apr 2012
CRUK internal database number: 563
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
